Hospital Infection Therapeutics Market Size, Development, Growth and Forecast to 2023
The hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal population in healthcare setting and high occurrence of numerous hospital infections. Increasing incidences of hospital infections, high number of pipeline drug molecules for specific treatment of healthcare associated infections and high unaddressed needs in most of the countries are some of the factors providing ample opportunities for the hospital infection therapeutics market to grow in the coming years.
North America leads the hospital infection therapeutics market followed by Europe. The North America hospital infection therapeutics market leads, due to improved healthcare awareness, high ratio of hospitals as compared to population of the region, increasing count of multi drug resistant microbial pathogens and increase in aging population of the region. Asia-Pacific is growing with an exponential rate, due to increased incidences of hospital infections and high demands of therapeutic drugs in the emerging countries such India and China.
Explore more about “Hospital Infection Therapeutics Market” at: https://www.psmarketresearch.com/market-analysis/hospital-infection-therapeutics-market
Hospital acquired infections are caused produced by viral pathogens, fungal and bacterial. Most of the hospital infections crop up from intensive care units. Varied range of hospital infections are being treated by various antimicrobial drugs. The patients staying in the hospitals develop several infections during their treatment. . The infections are known as hospital-acquired infections or hospital infections. The hospital acquired infections spread in the hospitals, rehabilitation centers, outpatient surgery centers, nursing homes and dialysis centers.
Some of the pipeline drugs available in the market for hospital acquired infections are MK-3415A, Amikacin Inhale, Oritavancin, Surotomycin, Ceftolozane, Dalvance, Plazomicin, Eravacycline, Tedizolid, Delafloxacin, and CAZ AVI. In 2011, according to the centers for disease control and prevention, around 1.6 million hospital acquired infections have been reported from all types of bacteria in US every year. Additionally, in 2013 about 4 million patients were identified with hospital acquired infections in Europe.
Request Table of Contents: https://www.psmarketresearch.com/market-analysis/Hospital-Infection-Therapeutics-Market/toc-sample
Some of the competitors in the hospital infection therapeutics market are: Cubist Pharmaceuticals, Inc., Actavis PLC, Johnson & Johnson Services, Inc., Bayer AG, GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Pfizer, Inc. and Sanofi.
